Locoregional recurrence in triple negative breast cancer: past, present, and future

被引:3
|
作者
Tran, Jennifer [1 ]
Thaper, Arushi [2 ]
Lopetegui-Lia, Nerea [1 ]
Ali, Azka [1 ]
机构
[1] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA
[2] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA
关键词
Local recurrence; locoregional recurrence; regional recurrence; triple negative breast cancer; transcriptome analysis; TUMOR-INFILTRATING LYMPHOCYTES; SURGICAL ADJUVANT BREAST; REGIONAL RECURRENCE; RADIATION-THERAPY; PREDICTIVE-VALUE; REIRRADIATION; CHEMOTHERAPY; MASTECTOMY; RECONSTRUCTION; HYPERTHERMIA;
D O I
10.1080/14737140.2023.2262760
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionTriple negative breast cancer (TNBC) is a rare but aggressive biological subtype of breast cancer associated with higher locoregional and distant recurrence rates and lower overall survival despite advancements in diagnostic and treatment strategies.Areas coveredThis review explores the evolving landscape of locoregional recurrence (LRR) in TNBC with improved surgical and radiation therapy delivery techniques including salvage breast conserving surgery (SBCS), re-irradiation, and thermo-radiation. We review current retrospective and prospective, albeit limited, clinical data highlighting the optimal management of locoregionally recurrent TNBC. We also discuss tumor genomic profiling and transcriptome analysis and review potential investigational directions.Expert opinionSignificant progress has been made in the prevention of LRR but rates remain suboptimal, particularly in the TNBC population, and outcomes following LRR are poor. Further prospective studies are needed to identify the most effective and safest systemic therapy regimens and to whom it should be offered. There has been growing interest in the role of molecular markers, genomic signatures, and tumor microenvironment in predicting outcomes and guiding LRR treatment. Transcriptome analyses and biomarker-driven investigations are currently being studied and represent a promising era of development in the management of LRR.
引用
收藏
页码:1085 / 1093
页数:9
相关论文
共 50 条
  • [31] Discusses the Past, Present, and Future of Breast Cancer Research
    Kalinsky, Kevin
    ONCOLOGY-NEW YORK, 2023, 37 (01):
  • [32] Hormonal intervention in breast cancer - Past, present, and future
    Osborne, MP
    BASIS FOR CANCER MANAGEMENT, 1996, 784 : 427 - 432
  • [33] Axillary surgery for breast cancer: past, present, and future
    Noguchi, Masakuni
    Inokuchi, Masafumi
    Noguchi, Miki
    Morioka, Emi
    Ohno, Yukako
    Kurita, Tomoko
    BREAST CANCER, 2021, 28 (01) : 9 - 15
  • [34] Genetic predisposition to breast cancer: Past, present, and future
    Turnbull, Clare
    Rahman, Nazneen
    ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2008, 9 : 321 - 345
  • [35] The past, present and future of breast cancer research in China
    Hong, Wei
    Dong, Erdan
    CANCER LETTERS, 2014, 351 (01) : 1 - 5
  • [36] Breast cancer susceptibily testing: past, present and future
    Goldberg, Jessica I.
    Borgen, Patrick I.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) : 1205 - 1214
  • [37] Past, Present, and Future Challenges in Breast Cancer Treatment
    Sledge, George W.
    Mamounas, Eleftherios P.
    Hortobagyi, Gabriel N.
    Burstein, Harold J.
    Goodwin, Pamela J.
    Wolff, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 1979 - 1986
  • [38] Axillary surgery for breast cancer: past, present, and future
    Masakuni Noguchi
    Masafumi Inokuchi
    Miki Noguchi
    Emi Morioka
    Yukako Ohno
    Tomoko Kurita
    Breast Cancer, 2021, 28 (1) : 9 - 15
  • [39] MANAGEMENT OF BREAST-CANCER - PAST, PRESENT, FUTURE
    CUNNINGHAM, RM
    SOUTHERN MEDICAL JOURNAL, 1976, 69 (03) : 260 - 265
  • [40] Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
    Asaoka, Mariko
    Gandhi, Shipra
    Ishikawa, Takashi
    Takabe, Kazuaki
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2020, 14